Christoph Ryffel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Christoph Ryffel has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Thomas Pilgrim
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
6 shared publications - Christoph Gräni
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
4 shared publications - Dominik C. Benz
Department of Nuclear Medicine, Cardiac Imaging, University Hospital of Zurich, Ramistrasse 100, CH-8091, Zurich, Switzerland; Advanced Clinician Scientist Program, University Medicine Zurich (UMZH), Switzerland; Department of Cardiology, University Hospital of Zurich, Ramistrasse 100, CH-8091, Zurich, Switzerland
3 shared publications - Ronny R. Buechel
Department of Nuclear Medicine, Cardiac Imaging, University Hospital Zurich, Zurich, Switzerland
3 shared publications - Stefan Stortecky
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
3 shared publications Stephan Windecker
Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
3 shared publications
Latest Publications
- 2 November 2026
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 20 (5) , 553-554
Reply to: “Coronary calcium to rule out obstructive coronary artery disease in patients with non-anginal chest pain”
- 2 November 2026
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
- Vol. 20 (5) , 553-554
Reply to: “Coronary calcium to rule out obstructive coronary artery disease in patients with non-anginal chest pain”
- Open Access
- 23 September 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (11) , 103335
Premature Ventricular Contractions at Extreme Altitude
- 23 September 2026
- Published by Elsevier in JACC: Advances
- Vol. 5 (11) , 103335
Open AccessPremature Ventricular Contractions at Extreme Altitude
- Open Access
- 16 September 2026
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- p. 1-15
Accuracy of CT-derived interarterial and intramural anomalous coronary arteries anatomy compared with 3D-reconstructed IVUS in-vivo reference
In anomalous aortic origin of a coronary artery (AAOCA), coronary CT angiography (CCTA) is the primary tool for anatomical assessment. However, CCTA measurements lack validation against a high-resolution in-vivo standard. To assess CCTA reliability for lumen dimensions and intramural length (IML) in AAOCA, and to validate these against a three-dimensionally reconstructed intravascular ultrasound (3D-IVUS) reference using three additional IML methodologies. A total of 60 AAOCA patients with an interarterial/intramural course underwent both CCTA and IVUS. A 3D-IVUS was constructed and its geometric reproducibility assessed. CCTA reliability and agreement with 3D-IVUS were evaluated for ostial dimensions, position-dependent minimal lumen area (MLA), and IML, measured by interluminal space thickness (ILS), elliptic ratio, and pericoronary fat sign. 3D-IVUS reference standard showed excellent geometric reproducibility (median point-wise distance 0.19 mm, 95%CI 0.07–0.43 mm) and good-to-excellent intrareader reliability (ICC 0.72–0.96). CCTA intra- and inter-reader reliability was moderate-to-excellent for ostial parameters and ILS-derived IML (ICC 0.69–0.92) and poor-to-good for MLA (ICC 0.28–0.87). Against 3D-IVUS, CCTA ostial area demonstrated moderate correlation (r = 0.73, p < 0.001) with minimal bias, and ILS-derived IML showed moderate agreement (r = 0.59; bias + 0.23 mm), while the fat sign substantially overestimated length (+ 7.88 mm). Using 3D-IVUS as an in-vivo reference standard for the precise assessment of coronary anatomy in AAOCA, CCTA provided reproducible ostial measurements, and the ILS-based method showed the best performance among the evaluated CCTA approaches for estimating intramural length. However, wide limits of agreement preclude precise individual sizing, and position-dependent MLA measurements remain unreliable. Graphical Abstract 60 patients with interarterial/intramural AAOCA (2 L-AAOCA, 58 R-AAOCA; mean age 53 ± 12 years, 30% female) underwent both CCTA and IVUS. IVUS pullbacks were used to construct a 3D reference model, from which ostial dimensions, minimal lumen area (MLA), and intramural (IM) length were automatically extracted at four anatomically defined landmarks (distal reference, end of intramural segment, MLA, ostium) and compared with corresponding CCTA measurements analyzed per current clinical standards. Reliability of 3D-IVUS and CCTA measurements was assessed by intraclass correlation coefficient (ICC); agreement between modalities was assessed by Bland-Altman analysis. Both modalities showed high reproducibility for ostial area (ICC 0.93 for IVUS, 0.87 for CCTA), whereas agreement between CCTA and 3D-IVUS was more variable across parameters, with the widest limits of agreement for IM length and MLA-related measurements. Abbreviations: AAOCA = Anomalous aortic origin of a coronary artery-AAOCA = Left anomalous aortic origin of a coronary artery, R-AAOCA = Right anomalous aortic origin of a coronary artery, CCTA = Coronary computed tomography angiography, IVUS = intravascular ultrasound, 3D-IVUS = three-dimensionally reconstructed IVUS, IM = intramural, MLA, minimal lumen area, ICC = intraclass correlation coefficient, Dist Ref, distal reference lumen, End IM = end of intramural course.
- 16 September 2026
- Published by Springer Nature in The International Journal of Cardiovascular Imaging
- p. 1-15
Open AccessAccuracy of CT-derived interarterial and intramural anomalous coronary arteries anatomy compared with 3D-reconstructed IVUS in-vivo reference
In anomalous aortic origin of a coronary artery (AAOCA), coronary CT angiography (CCTA) is the primary tool for anatomical assessment. However, CCTA measurements lack validation against a high-resolution in-vivo standard. To assess CCTA reliability for lumen dimensions and intramural length (IML) in AAOCA, and to validate these against a three-dimensionally reconstructed intravascular ultrasound (3D-IVUS) reference using three additional IML methodologies. A total of 60 AAOCA patients with an interarterial/intramural course underwent both CCTA and IVUS. A 3D-IVUS was constructed and its geometric reproducibility assessed. CCTA reliability and agreement with 3D-IVUS were evaluated for ostial dimensions, position-dependent minimal lumen area (MLA), and IML, measured by interluminal space thickness (ILS), elliptic ratio, and pericoronary fat sign. 3D-IVUS reference standard showed excellent geometric reproducibility (median point-wise distance 0.19 mm, 95%CI 0.07–0.43 mm) and good-to-excellent intrareader reliability (ICC 0.72–0.96). CCTA intra- and inter-reader reliability was moderate-to-excellent for ostial parameters and ILS-derived IML (ICC 0.69–0.92) and poor-to-good for MLA (ICC 0.28–0.87). Against 3D-IVUS, CCTA ostial area demonstrated moderate correlation (r = 0.73, p < 0.001) with minimal bias, and ILS-derived IML showed moderate agreement (r = 0.59; bias + 0.23 mm), while the fat sign substantially overestimated length (+ 7.88 mm). Using 3D-IVUS as an in-vivo reference standard for the precise assessment of coronary anatomy in AAOCA, CCTA provided reproducible ostial measurements, and the ILS-based method showed the best performance among the evaluated CCTA approaches for estimating intramural length. However, wide limits of agreement preclude precise individual sizing, and position-dependent MLA measurements remain unreliable. Graphical Abstract 60 patients with interarterial/intramural AAOCA (2 L-AAOCA, 58 R-AAOCA; mean age 53 ± 12 years, 30% female) underwent both CCTA and IVUS. IVUS pullbacks were used to construct a 3D reference model, from which ostial dimensions, minimal lumen area (MLA), and intramural (IM) length were automatically extracted at four anatomically defined landmarks (distal reference, end of intramural segment, MLA, ostium) and compared with corresponding CCTA measurements analyzed per current clinical standards. Reliability of 3D-IVUS and CCTA measurements was assessed by intraclass correlation coefficient (ICC); agreement between modalities was assessed by Bland-Altman analysis. Both modalities showed high reproducibility for ostial area (ICC 0.93 for IVUS, 0.87 for CCTA), whereas agreement between CCTA and 3D-IVUS was more variable across parameters, with the widest limits of agreement for IM length and MLA-related measurements. Abbreviations: AAOCA = Anomalous aortic origin of a coronary artery-AAOCA = Left anomalous aortic origin of a coronary artery, R-AAOCA = Right anomalous aortic origin of a coronary artery, CCTA = Coronary computed tomography angiography, IVUS = intravascular ultrasound, 3D-IVUS = three-dimensionally reconstructed IVUS, IM = intramural, MLA, minimal lumen area, ICC = intraclass correlation coefficient, Dist Ref, distal reference lumen, End IM = end of intramural course.
- Open Access
- 3 July 2026
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
Coronary calcium to rule out obstructive coronary artery disease in patients with non-anginal chest pain
- 3 July 2026
- Published by Elsevier in Journal of Cardiovascular Computed Tomography
Open AccessCoronary calcium to rule out obstructive coronary artery disease in patients with non-anginal chest pain
- Open Access
Prognostic value of artificial intelligence-derived echocardiographic measurements in transthyretin cardiomyopathy
STRUCTURED Background: Transthyretin cardiomyopathy (ATTR-CM) is a progressive, potentially fatal disease requiring accurate risk stratification. Echocardiography is the first-line imaging modality, with AI-based tools increasingly applied for automated analysis, yet their prognostic value remains unknown. Objectives: To examine the prognostic value of AI-derived echocardiographic measurements and their incremental value beyond biomarker staging in ATTR-CM. Methods: This retrospective study included patients from two ATTR-CM registries. Baseline echocardiograms were analyzed using the fully automated AI-based software Us2.ai. Prognostic performance was assessed by Kaplan-Meier analysis, Cox regression, and ROC curves. A two-parameter echocardiographic staging system combining left ventricular (LV) global longitudinal strain (GLS) and right ventricular (RV) fractional area change (FAC) stratified patients into low (both normal), intermediate (one abnormal), and high risk (both abnormal). Results: Among 347 patients (91% male, median age 78 years), 141 experienced all-cause death or heart failure hospitalization over a median follow-up of 2.4 years. In multivariable analysis, AI-derived LV-GLS (HR 1.13 [1.03-1.25], p=0.011) and RV FAC (HR 0.96 [0.93-0.99], p=0.014) were independent outcome predictors. Echo staging stratified risk into groups with 3-fold (95% CI 1.70-5.91) and 6-fold (95% CI 3.22-10.30) increased hazard compared to low risk (p<0.001), with incremental prognostic value beyond National Amyloidosis Centre (NAC) staging and age (chi-square from 53 to 80; p0.05). Conclusion: AI-derived echocardiographic measurements demonstrate independent and incremental prognostic value beyond biomarker-based NAC staging in ATTR-CM, comparable to human measurements, supporting their integration into clinical risk stratification.
Open AccessPrognostic value of artificial intelligence-derived echocardiographic measurements in transthyretin cardiomyopathy
STRUCTURED Background: Transthyretin cardiomyopathy (ATTR-CM) is a progressive, potentially fatal disease requiring accurate risk stratification. Echocardiography is the first-line imaging modality, with AI-based tools increasingly applied for automated analysis, yet their prognostic value remains unknown. Objectives: To examine the prognostic value of AI-derived echocardiographic measurements and their incremental value beyond biomarker staging in ATTR-CM. Methods: This retrospective study included patients from two ATTR-CM registries. Baseline echocardiograms were analyzed using the fully automated AI-based software Us2.ai. Prognostic performance was assessed by Kaplan-Meier analysis, Cox regression, and ROC curves. A two-parameter echocardiographic staging system combining left ventricular (LV) global longitudinal strain (GLS) and right ventricular (RV) fractional area change (FAC) stratified patients into low (both normal), intermediate (one abnormal), and high risk (both abnormal). Results: Among 347 patients (91% male, median age 78 years), 141 experienced all-cause death or heart failure hospitalization over a median follow-up of 2.4 years. In multivariable analysis, AI-derived LV-GLS (HR 1.13 [1.03-1.25], p=0.011) and RV FAC (HR 0.96 [0.93-0.99], p=0.014) were independent outcome predictors. Echo staging stratified risk into groups with 3-fold (95% CI 1.70-5.91) and 6-fold (95% CI 3.22-10.30) increased hazard compared to low risk (p<0.001), with incremental prognostic value beyond National Amyloidosis Centre (NAC) staging and age (chi-square from 53 to 80; p0.05). Conclusion: AI-derived echocardiographic measurements demonstrate independent and incremental prognostic value beyond biomarker-based NAC staging in ATTR-CM, comparable to human measurements, supporting their integration into clinical risk stratification.
- Open Access
- 28 October 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (20) , 2505-2516
Long-Term Outcomes in Moderate and Severe Aortic Stenosis According to Extent of Cardiac Damage
- 28 October 2025
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 18 (20) , 2505-2516
Open AccessLong-Term Outcomes in Moderate and Severe Aortic Stenosis According to Extent of Cardiac Damage
- Open Access
- 1 October 2025
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 18 (12) , 1389-1395
Variations of Severely Reduced Myocardial Flow Reserve in PET Myocardial Perfusion Imaging
- 1 October 2025
- Published by Elsevier in JACC: Cardiovascular Imaging
- Vol. 18 (12) , 1389-1395
Open AccessVariations of Severely Reduced Myocardial Flow Reserve in PET Myocardial Perfusion Imaging
- Open Access
- 15 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-11
Colchicine in patients with aortic stenosis undergoing transcatheter aortic valve replacement: a double-blind randomized trial
An inflammatory process may increase the risk of arrhythmias after transcatheter aortic valve replacement (TAVR). In this single-centre, double-blind, placebo-controlled, randomized trial we investigated the efficacy of colchicine to reduce a composite of new-onset atrial fibrillation or atrioventricular conduction disturbances requiring the implantation of a permanent pacemaker at 30 days after TAVR. Between September 21, 2021 and April 25, 2024, 120 patients with aortic stenosis undergoing TAVR (mean age 80.6 ± 5 years, 64% male) were randomly allocated to treatment with colchicine (n = 60) or placebo (n = 60). The trial was prematurely stopped due to a higher rate of stroke in the experimental group in a pre-specified interim analysis (5 [8.3%] versus 0 at maximum available follow-up, p = 0.022). In the intention-to-treat population, the primary endpoint occurred in 6 patients (10%) in the colchicine group and in 15 patients (25%) in the placebo group (risk-difference −15.0%, 95% CI −28.3 to −1.7, p = 0.031). The prespecified imaging endpoint, subclinical leaflet thrombosis, was detected in 13 of 48 patients (27%) in the colchicine group versus 26 of 48 patients (54%) in the placebo group (risk difference −27.1%. 95% CI −46.0% to −8.2%, p = 0.007). Here, we show that periprocedural treatment with colchicine may reduce the incidence of new-onset arrhythmias and subclinical leaflet thrombosis after TAVR. However, given the premature termination of the trial due to an unexpected increase in the stroke rate among patients treated with colchicine, confirmatory trials are warranted to corroborate the effect of anti-inflammatory treatment on the incidence of arrhythmias and subclinical leaflet thrombosis after TAVR. The trial was an investigator-initiated study supported by dedicated grants from the Bangerter-Rhyner Foundation and the Swiss Life Foundation. ClinicalTrials.gov Identifier: NCT04870424.
- 15 July 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-11
Open AccessColchicine in patients with aortic stenosis undergoing transcatheter aortic valve replacement: a double-blind randomized trial
An inflammatory process may increase the risk of arrhythmias after transcatheter aortic valve replacement (TAVR). In this single-centre, double-blind, placebo-controlled, randomized trial we investigated the efficacy of colchicine to reduce a composite of new-onset atrial fibrillation or atrioventricular conduction disturbances requiring the implantation of a permanent pacemaker at 30 days after TAVR. Between September 21, 2021 and April 25, 2024, 120 patients with aortic stenosis undergoing TAVR (mean age 80.6 ± 5 years, 64% male) were randomly allocated to treatment with colchicine (n = 60) or placebo (n = 60). The trial was prematurely stopped due to a higher rate of stroke in the experimental group in a pre-specified interim analysis (5 [8.3%] versus 0 at maximum available follow-up, p = 0.022). In the intention-to-treat population, the primary endpoint occurred in 6 patients (10%) in the colchicine group and in 15 patients (25%) in the placebo group (risk-difference −15.0%, 95% CI −28.3 to −1.7, p = 0.031). The prespecified imaging endpoint, subclinical leaflet thrombosis, was detected in 13 of 48 patients (27%) in the colchicine group versus 26 of 48 patients (54%) in the placebo group (risk difference −27.1%. 95% CI −46.0% to −8.2%, p = 0.007). Here, we show that periprocedural treatment with colchicine may reduce the incidence of new-onset arrhythmias and subclinical leaflet thrombosis after TAVR. However, given the premature termination of the trial due to an unexpected increase in the stroke rate among patients treated with colchicine, confirmatory trials are warranted to corroborate the effect of anti-inflammatory treatment on the incidence of arrhythmias and subclinical leaflet thrombosis after TAVR. The trial was an investigator-initiated study supported by dedicated grants from the Bangerter-Rhyner Foundation and the Swiss Life Foundation. ClinicalTrials.gov Identifier: NCT04870424.
- Open Access
- 21 October 2024
- Published by Wiley in Echocardiography
- Vol. 41 (10) , e15960
Multimodality Imaging in the Management of Tricuspid Valve Regurgitation
Approximately 5% of elderly patients suffer from moderate or severe tricuspid valve regurgitation, which is an independent predictor of high morbidity and mortality. Surgical treatment of isolated tricuspid valve regurgitation has been associated with elevated fatality rate, leading to a growing interest in minimal invasive, transcatheter‐based therapies such as transcatheter edge‐to‐edge repair and transcatheter valve replacement. Nevertheless, despite high procedural efficacy and safety of transcatheter‐based therapies, a number of challenges limit their rapid adoption in routine clinical practice. In particular, the wide range of transcatheter approaches to address the significant variability in tricuspid valve pathology challenges the reproducibility of clinical outcomes. Multimodality imaging is pivotal for grading the regurgitation severity, determining the underlying pathology, assessing RV function and pulmonary pressures, identifying concomitant cardiac disease, and selecting the most beneficial treatment modality and access. This article reviews the role of different imaging modalities in guiding the management of patients with significant tricuspid valve regurgitation.
- 21 October 2024
- Published by Wiley in Echocardiography
- Vol. 41 (10) , e15960
Open AccessMultimodality Imaging in the Management of Tricuspid Valve Regurgitation
Approximately 5% of elderly patients suffer from moderate or severe tricuspid valve regurgitation, which is an independent predictor of high morbidity and mortality. Surgical treatment of isolated tricuspid valve regurgitation has been associated with elevated fatality rate, leading to a growing interest in minimal invasive, transcatheter‐based therapies such as transcatheter edge‐to‐edge repair and transcatheter valve replacement. Nevertheless, despite high procedural efficacy and safety of transcatheter‐based therapies, a number of challenges limit their rapid adoption in routine clinical practice. In particular, the wide range of transcatheter approaches to address the significant variability in tricuspid valve pathology challenges the reproducibility of clinical outcomes. Multimodality imaging is pivotal for grading the regurgitation severity, determining the underlying pathology, assessing RV function and pulmonary pressures, identifying concomitant cardiac disease, and selecting the most beneficial treatment modality and access. This article reviews the role of different imaging modalities in guiding the management of patients with significant tricuspid valve regurgitation.